Clinical trials
Infusion clinical trials
Below are recruiting infusion clinical trials, each written for real people, not researchers. We’re tracking 511 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04086485RecruitingPhase 1/Phase 2
Lu-177 dotatate plus olaparib for inoperable neuroendocrine tumors
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
Bethesda, MarylandAges 18–100 - NCT04099797RecruitingPhase 1
CAR T therapy for certain GD2 brain tumors
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
Houston, TexasAges 1–25 - NCT04166877RecruitingPhase 4
Magnesium drip to reduce pain in ICU trauma patients
This trial tests whether a magnesium infusion can better control pain in adults who have serious injuries and need intensive care. It compares magnesium as part of pain treatment to standard pain care to see if pain improves and stays controlled.
Sacramento, CaliforniaAges 18 years+ - NCT04180059RecruitingPhase 1
Anti-DP treatment after stem cell transplant to prevent relapse
This early-phase trial tests an anti-DP medicine given after an allogeneic (donor) stem cell transplant. It aims to improve outcomes by targeting immune cells linked to certain transplant match types and reducing relapse risk.
NantesAges 18–75 - NCT04207619Recruiting
Check an MRI blood-sugar response marker in healthy adults
This study tests whether a substance measured from blood and MRI signals can predict how your body fights low blood sugar. It’s done in healthy adults to see if the marker could help in future low-blood-sugar risk tracking.
Baton Rouge, LouisianaAges 18–40 - NCT04211675RecruitingPhase 1/Phase 2
Test NK cell infusions with irinotecan, temozolomide, and dinutuximab
This early-phase study tests whether giving donated NK cells with three medicines can shrink neuroblastoma that has come back or not responded well to prior treatment. It’s designed for people who have limited options, and the goal is to see safety and whether the combination works.
Columbus, OhioAges Up to 29 years - NCT04224558RecruitingPhase 1/Phase 2
Stem cell transplant for hard-to-control Crohn’s disease
This early-phase study tests whether a stem cell transplant can improve Crohn’s disease in teens and young adults whose disease is active and not responding to standard medicines. It may help some people who are not doing well despite several prior treatments, but it also involves intensive study procedures and safety checks.
Los Angeles, CaliforniaAges 13–28 - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT04558736RecruitingPhase 2
Haploidentical transplant for severe aplastic anemia in children
This trial tests a “half-matched” stem cell transplant for children and teens with severe aplastic anemia when a fully matched donor isn’t available. It may help rebuild blood-making cells after prior treatments did not work well enough.
Memphis, TennesseeAges Up to 21 years - NCT04616209RecruitingPhase 1/Phase 2
Donor immune cell therapy for advanced lung cancer
This early-phase study tests immune cells given from a matched donor to treat advanced non-small-cell lung cancer. It aims to see how safe the treatment is and whether it can help control the cancer.
TaipeiAges 20–70 - NCT04650321RecruitingPhase 4
Home infusions of ocrelizumab for some people with MS
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
Centennial, ColoradoAges 18–55 - NCT04815356RecruitingPhase 1
T cells designed to attack a blood cancer called hairy cell leukemia
This early-stage (Phase 1) study tests a new type of treatment made from your T cells (immune cells) that are programmed to find and kill cancer cells with a specific marker (CD22). It’s designed for people with hairy cell leukemia that has come back or didn’t respond to prior treatments, and it aims to see safety and how well the approach works.
Bethesda, MarylandAges 18 years+ - NCT04837885RecruitingPhase 2
Liver-targeted radioactive drug for GI or pancreas NET liver spread
This study tests a way to deliver a radioactive “somatostatin-type” medicine directly into the liver artery to treat liver-dominant spread of neuroendocrine tumors (NETs). It may help shrink or control liver metastases after standard treatment has not worked enough.
BordeauxAges 18 years+ - NCT04874038RecruitingPhase 3
Lidocaine infusions to prevent long-lasting pain after breast surgery
This Phase 3 study tests whether receiving lidocaine through an IV during breast surgery can lower the chance of ongoing pain afterward. If it works, it may help some people avoid chronic, surgery-related pain in the chest wall, shoulder, or arm.
Calgary, AlbertaAges 18–100 - NCT05650632RecruitingPhase 1
IV infusion safety study of etentamig for multiple myeloma
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
Phoenix, ArizonaAges 18 years+ - NCT05003388RecruitingPhase 1
Safety study of IV stem cells from donor umbilical cord
This early study tests whether an IV infusion of donor-derived stem cells is safe for people with multiple sclerosis. It mainly focuses on side effects and safety, not whether it improves MS symptoms yet.
St John'sAges Any age - NCT05003960RecruitingPhase 1
Testing an IV stem cell treatment for autism safety
This trial tests whether an IV infusion of lab-made donor stem cells is safe for people with autism. It mainly looks at side effects and whether the treatment can be given without causing harm.
St John'sAges Any age - NCT05003947RecruitingPhase 1
Stem cell infusion for Crohn’s or ulcerative colitis safety
This Phase 1 trial tests whether an IV infusion of donated (allogeneic) stem cells is safe in people with Crohn’s disease or ulcerative colitis. It focuses mainly on safety and tolerability, and it may offer a new treatment approach if you qualify.
St John'sAges Any age - NCT05003934RecruitingPhase 1
IV stem cell treatment safety study for rheumatoid arthritis
This Phase 1 trial tests how safe an intravenous (through a vein) stem cell product is for people with rheumatoid arthritis. It is mainly looking for side effects and safety rather than proving it works yet.
St John'sAges Any age - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05016817RecruitingPhase 1
Testing an IV stem cell treatment for idiopathic pulmonary fibrosis
This Phase 1 study tests whether an IV infusion of stem cells from donated umbilical cord tissue is safe for people with idiopathic pulmonary fibrosis. It focuses mainly on safety and tolerability, and it may help by offering a new treatment approach if the cells are safe for you.
St John'sAges Any age - NCT05016804RecruitingPhase 1
Umbilical cord stem cell infusion trial for systemic sclerosis
This early safety study tests whether an intravenous (through a vein) stem cell product made from donated umbilical cord cells is safe for people with systemic sclerosis. If you join, the goal is to see how your body tolerates the treatment and monitor for side effects.
St John'sAges Any age - NCT05018845RecruitingPhase 1
Testing a donated stem cell treatment for chronic kidney disease
This early study (Phase 1) tests whether an intravenously given, donated stem cell product is safe for people with chronic kidney disease. It mainly looks at side effects and whether the treatment can be given without harming you.
St John'sAges Any age - NCT05018819RecruitingPhase 1
IV stem cell treatment for cerebral palsy safety
This trial tests whether an IV infusion of lab-grown stem cells from donated umbilical cord is safe for people with cerebral palsy. It mainly focuses on side effects and safety rather than proving it works.
St John'sAges Any age
Hear when a new Infusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for infusion?
- Yes. Clin2 currently lists 511 recruiting infusion studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a infusion trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a infusion trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.